Enterprise Value

1.331B

Cash

213.6M

Avg Qtr Burn

N/A

Short % of Float

32.92%

Insider Ownership

4.28%

Institutional Own.

98.66%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Abiprubart (KPL-404) (CD40) Details
Autoimmune disease, Sjögren-Larsson Syndrome

Phase 2b

Data readout

Vixarelimab (OSMRβ) (KPL-716) Details
Skin disease/disorder, Prurigo nodularis

Phase 2b

Update

Abiprubart (KPL-404) (CD40) Details
Autoimmune disease, Rheumatoid arthritis

Phase 2

Update

Mavrilimumab (GM-CSFRa) Details
Inflammatory disease, Giant cell arteritis

Failed

Discontinued

Failed

Discontinued